Replies to post #1077 on Biostar Pharmaceuticals, Inc. (BSPM)

[GorillaGorilla]

That sounds about what I would say...

As long as they get near enough to their estimate that's fine - within a million or 2. It's not like were priced for perfection.

Then the auditor and the cash flow remains strong (maybe Q1 may be better for cash after Q4's ramp-up?). And they use their cash wisely - show they are not another Chinese firm that just dilutes.

Approval of Zushima is probably out of their hands?

I think it's all going to be sector driven - but this could be more transparent than most. Should explain what happened to that herb project. Now, can we get them to be as shareholder friendly as CCME! :-)

rich

[Florinda]

"I think $3 is a guarantee in the next 6 months and $4 looks good as well by year end"--Michael Anderson

Wow, I'm shocked that you think that the share price is only apt to go up .50 or so over the next 6 months and up to only to $4 range for the year. So evidently you think the Rodman & Renshaw price target of $7 is way off. Again, with Q4 traditionally their best and the stock down so much and yet only expecting in six months a 20% rise in share price. Whoa to shareholders if the report isn't stellar.

Steve